Bankole Johnson launches first U.S. clinical use of MUSE-infused regenerative protein arrays

By AI, Created 6:41 AM UTC, June 03, 2026, /AGP/ – Prof. Dr. Bankole A. Johnson has announced the first U.S. clinical integration of MUSE-infused Regenerative Protein Arrays across his Miami facilities. The move pairs advanced genomic diagnostics with non-cellular regenerative therapy in a push toward more personalized neurological and restorative care.

Why it matters: - The clinical integration adds a non-cellular regenerative platform to patient care aimed at neurological restoration, recovery and broader restorative medicine. - The approach combines precision diagnostics with regenerative signaling biology, which could reshape how highly individualized protocols are built and delivered. - The announcement highlights a shift away from symptom management and toward biologically informed restoration strategies.

What happened: - Prof. Dr. Bankole A. Johnson announced the first U.S. clinical application of MUSE-infused Regenerative Protein Arrays. - The integration is being used across Casa Privée, the Institute of Regenerative Medicine & Neuroscience (IRMN), and the Miami Stem Cell Clinic in Miami, Florida. - The platform uses Genesis Regenerative’s acellular RPA to deliver biologically active repair mediators and targeted paracrine signaling. - Dr. Johnson said his team was first in the United States to clinically integrate MUSE-cell-derived biologic concepts into a broader regenerative signaling platform directed at neurological restoration and recovery.

The details: - Dr. Johnson is Oxford-trained and holds doctorates in neuropsychopharmacology, science from the University of Glasgow and molecular genetics. - Dr. Johnson is board-certified in psychiatry, addiction medicine and regenerative medicine. - The MUSE biology framework is described as having stress resistance, tissue-homing potential and immune privilege features. - The acellular RPA approach is presented as avoiding blood draws and the risk of cellular or DNA transfer. - Precision diagnostics are central to the protocol. - The clinic uses Genome-Wide Association Studies (GWAS), whole-exome genome testing and mRNA expression measurements to map a patient’s cellular environment, autonomic function and regenerative reserve. - The protocol is designed to reduce chronic neuroinflammatory burden and oxidative cellular stress. - The strongest clinical observations occur when the MUSE-infused RPA is paired with peptide signaling support, mitochondrial optimization, neuroplasticity enhancement and hyperbaric oxygen therapy. - Dr. Johnson called the work a translational bridge between advanced neuroscience and regenerative medicine.

Between the lines: - The announcement positions genomic data as the guide for selecting regenerative interventions, which reflects a broader push toward personalized medicine. - The framing also suggests Genesis Regenerative’s RPA is being used as a standardized delivery platform for biologic signaling rather than as a cell-based treatment. - The emphasis on scientific rigor signals awareness that MUSE-based regenerative claims will likely face scrutiny as clinical use expands.

What’s next: - Dr. Johnson’s clinics are likely to continue refining multi-modal protocols built around inflammatory profile, neurological phenotype and metabolic status. - The integration may set up further clinical observation around whether genomic diagnostics and non-cellular regenerative therapies improve outcomes in restorative care. - More information is available from Casa Privée, Miami Stem Cell Clinic, and Genesis Regenerative.